Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Robert S. Fishman sold 8,000 shares of the company’s stock in a transaction on Friday, September 7th. The shares were sold at an average price of $14.57, for a total value of $116,560.00. Following the sale, the insider now owns 8,000 shares of the company’s stock, valued at $116,560. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Shares of CORT stock traded up $0.09 on Tuesday, hitting $14.57. 1,055,400 shares of the company’s stock were exchanged, compared to its average volume of 1,528,712. Corcept Therapeutics Incorporated has a 12 month low of $11.55 and a 12 month high of $25.96. The company has a market cap of $1.72 billion, a P/E ratio of 32.70 and a beta of 1.55.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Thursday, August 9th. The biotechnology company reported $0.20 earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.04). Corcept Therapeutics had a return on equity of 38.53% and a net margin of 68.32%. The business had revenue of $62.31 million for the quarter, compared to the consensus estimate of $68.49 million. During the same quarter in the prior year, the company earned $0.13 earnings per share. Corcept Therapeutics’s quarterly revenue was up 75.2% compared to the same quarter last year. analysts anticipate that Corcept Therapeutics Incorporated will post 0.6 EPS for the current year.

Several hedge funds have recently made changes to their positions in CORT. BlackRock Inc. lifted its position in shares of Corcept Therapeutics by 13.2% during the 1st quarter. BlackRock Inc. now owns 12,905,164 shares of the biotechnology company’s stock worth $212,288,000 after buying an additional 1,505,877 shares during the last quarter. Nexthera Capital LP bought a new stake in shares of Corcept Therapeutics during the 1st quarter worth $17,193,000. Ingalls & Snyder LLC lifted its position in shares of Corcept Therapeutics by 7.3% during the 2nd quarter. Ingalls & Snyder LLC now owns 7,316,990 shares of the biotechnology company’s stock worth $115,023,000 after buying an additional 499,450 shares during the last quarter. Fuller & Thaler Asset Management Inc. bought a new stake in shares of Corcept Therapeutics during the 2nd quarter worth $6,891,000. Finally, KBC Group NV bought a new stake in shares of Corcept Therapeutics during the 2nd quarter worth $5,803,000. Institutional investors and hedge funds own 74.79% of the company’s stock.

A number of analysts have recently weighed in on the company. ValuEngine downgraded Corcept Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, August 13th. B. Riley cut their target price on Corcept Therapeutics from $30.00 to $22.00 and set a “buy” rating for the company in a research report on Monday, August 13th. BidaskClub downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, July 14th. Finally, Stifel Nicolaus downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating and set a $20.00 target price for the company. in a research report on Thursday, May 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. Corcept Therapeutics has a consensus rating of “Buy” and an average price target of $21.83.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression.

Featured Story: Price to Earnings Ratio (PE), For Valuing Stocks

Insider Buying and Selling by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.